Development of Oral Azacitidine With Cedazuridine for Myelodysplastic Syndrome (MDS) and Myeloproliferative Neoplasms (MPN) Including Chronic Myelomonocytic Leukemia (CMML) by Targeting Pharmacokinetic AUC Equivalence vs Subcutaneous Azacitidine

被引：0

作者：

Garcia-Manero, Guillermo ^{[1
]}

McCloskey, James ^{[2
]}

Scott, Bart L. ^{[3
]}

Griffiths, Elizabeth A. ^{[4
]}

Kiner-Strachan, Bonnie ^{[5
]}

Roboz, Gail J. ^{[6
,7
]}

Meyer, Janelle ^{[8
]}

Chan, Winny ^{[9
]}

Sano, Yuri ^{[9
]}

Oganesian, Aram ^{[9
]}

Keer, Harold K. ^{[9
]}

Savona, Michael R. ^{[10
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[2] Hackensack Med Ctr, John Thuerer Canc Ctr, Hackensack, NJ USA

[3] Fred Hutchinson Canc Ctr, Seattle, WA USA

[4] Roswell Park Comprehens Canc Ctr, Buffalo, NY USA

[5] NYU Langone Hlth, Perlmutter Canc Ctr, New York, NY USA

[6] Weill Cornell Med, New York, NY USA

[7] NewYork Presbyterian Hosp, New York, NY USA

[8] Oregon Oncol Specialists, Salem, OR USA

[9] Taiho Oncol Inc, Pleasanton, CA USA

[10] Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Sch Med, Nashville, TN USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷

关键词：

MDS; ASTX030; azacitidine; cedazuridine; oral hypomethylating agents; myelodysplastic syndromes; CMML;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MDS-773

引用

页码：S406 / S407

页数：2

共 42 条

[21] Phase 2 study of pevonedistat (P) plus azacitidine (A) versus azacitidine in patients (pts) with higher-risk myelodysplastic syndromes (MDS)/chronic myelomonocytic leukemia (CMML) or low-blast acute myelogenous leukemia (LB-AML) (NCT02610777)
Giagounidis, A.
Ades, L.
Watts, J.
Radinoff, A.
Arnan Sangerman, M.
Cerrano, M.
Font Lopez, P.
Zeidner, J.
Diez Campelo, M.
Graux, C.
Liesveld, J.
Selleslag, D.
Tzvetkov, N.
Fram, R. J.
Zhao, D.
Bell, J.
Friedlander, S.
Faller, D. V.
Sekeres, M. A.
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 171 - 171
[22] Phazar: A Phase Ib Study to Assess the Safety and Tolerability of Ruxolitinib in Combination with Azacitidine in Advanced Phase Myeloproliferative Neoplasms (MPN), Including Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukaemia (AML) Arising from MPN [ISRCTN16783472]
Drummond, Mark W.
Gaskell, Charlotte
Harrison, Claire
Mead, Adam J.
Yap, Christina
Jackson, Aimee E.
Byrne, Jennifer
Clark, Fiona J.
Narayanan, Srinivasan
Bowen, David
Somervaille, Tim C. P.
Gudgin, Emma
Milojkovic, Dragana
Fletcher, Rachel S.
Brierley, Charlotte K.
Knapper, Steve
BLOOD, 2020, 136
[23] Phase 2 Study of Pevonedistat plus Azacitidine versus Azacitidine in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)/Chronic Myelomonocytic Leukemia (CMML) or Low-Blast Acute Myelogenous Leukemia (LB-AML) (NCT02610777): Subset Analysis in Higher-Risk MDS
Watts, Justin
Ades, Lionel
Radinoff, Atanas
Arnan Sangerman, Montserrat
Cerrano, Marco
Font Lopez, Patricia
Zeidner, Joshua
Campelo, Maria Diez
Graux, Carlos
Liesveld, Jane
Selleslag, Dominik
Tzvetkov, Nikolay
Fram, Robert J.
Zhao, Dan
Bell, Jill
Friedlander, Sharon
Faller, Douglas V.
Sekeres, Mikkael A.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S323 - S324
[24] A Phase I/II Study of Venetoclax in Combination with ASTX727 (cedazuridine/decitabine) in Treatment-Naive High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)
Venugopal, Sangeetha
Kantarjian, Hagop
Maiti, Abhishek
Short, Nicholas J.
Montalban-Bravo, Guillermo
Alvarado, Yesid
Chien, Kelly S.
Kanagal-Shamanna, Rashmi
Pemmaraju, Naveen
Davel, Naval
Kadia, Tapan M.
Borthakur, Gautam
Jabbour, Elias J.
Garcia-Manero, Guillermo
BLOOD, 2021, 138
[25] Health-related quality of life (HRQoL) in patients with untreated higher-risk myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and chronic myelomonocytic leukemia (CMML) receiving glasdegib plus azacitidine (AZA).
Wang, Eunice S.
Bell, Timothy
Zeidan, Amer Methqal
Bhattacharyya, Helen
Kudla, Art
Chan, Geoffrey
Sekeres, Mikkael A.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[26] Glasdegib in combination with azacitidine (AZA) in patients (pts) with untreated higher-risk myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML): Effects on marrow recovery and transfusion independence.
Zeidan, Amer Methqal
Schuster, Michael
Joris, Magalie
Krauter, Jurgen
Maertens, Johan
Gyan, Emmanuel
Kovacsovics, Tibor
Verma, Amit
Vyas, Paresh
Wang, Eunice S.
Ma, Wendy
Zeremski, Mirjana
Kudla, Art
Chan, Geoffrey
Sekeres, Mikkael A.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[27] Pre-Transplant Azacitidine and Allogeneic Hematopoietic Cell Transplant (HCT) Outcomes of One Hundred Fifty-Nine Patients up to Age Seventy-Five with Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)
Field, Teresa
Perkins, Janelle
Hillgruber, Ryan
Nishihori, Taiga
Tomblyn, Marcie R.
Mishra, Asmita
Pidala, Joseph
Locke, Frederick
Perez, Lia Elena
Betts, Brian
Ayala, Ernesto
Alsina, Melissa
Ochoa, Jose-Leonel
Padron, Eric
Lancet, Jeffery
Fernandez, Hugo
List, Alan F.
Komrokji, Rami
Kharfan-Dabaja, Mohamed
Anasetti, Claudio
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2014, 20 (02) : S221 - S222
[28] A Phase I/II Study of Venetoclax in Combination With ASTX727 (Decitabine/Cedazuridine) in Treatment-Naive High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)
Venugopal, Sangeetha
Kantarjian, Hagop
Maiti, Abhishek
Short, Nicholas J.
Montalban-Bravo, Guillermo
Alvarado, Yesid
Chien, Kelly
Kanagal-Shamanna, Rashma
Pemmaraju, Naveen
Daver, Naval
Kadia, Tapan
Borthakur, Gautam
Jabbour, Elias
Garcia-Manero, Guillermo
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S321 - S321
[29] Model-based analysis to support dose selection of pevonedistat (PEV) combined with azacitidine (AZA) in patients (pts) with higher-risk myelodysplastic syndromes (MDS)/chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML).
Zhou, Xiaofei
Mould, Diane R.
Zhao, Dan
Sekeres, Mikkael A.
Ades, Lionel
Swords, Ronan T.
Handa, Hiroshi
Fram, Robert J.
Faller, Douglas V.
Tsukurov, Olga
Gupta, Neeraj
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[30] A Phase Ib Study to Assess the Safety and Tolerability of Ruxolitinib in Combination with Azacitidine in Patients with Advanced Phase Myeloproliferative Neoplasms (MPN), Including Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukaemia (AML) Arising from MPN (The Bloodwise / TAP PHAZAR Study on Behalf of the UK MPN CSG)
Drummond, Mark W.
Harrison, Claire N.
Vicente, Samuel Munoz
Mead, Adam J.
Yap, Christina
Chen, Frederick
Narayanan, Srinivasan
Milojkovic, Dragana
Navarro-Nunez, Leyre
Knapper, Steven
BLOOD, 2017, 130

← 1 2 3 4 5 →